EMA approves biomarker study of mitochondrial stimulator for neurodegenerative diseases

The European Medicines Agency has approved enrollment for a phase 1/2a biomarker study to examine a once-daily, oral, brain penetrant mitochondrial stimulator to treat a range of neurological and neuromuscular conditions.
According to a release from Mitochon Pharmaceuticals, its MP101 therapeutic aims to improve central nervous system survival and function and will be tested in a 14-day pilot study to assess safety and significant change in disease-specific biomarkers for those with amyotrophic lateral sclerosis, MS, Huntington’s disease and Alzheimer’s disease.
In preclinical

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart